VYNE Therapeutics Inc (VYNE)

[realfast95]

Insiders had their options moved forward.


(1) On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.


Chief Scientific Officer
12/11/2019 M 80300
12/11/2019 F 27766 D $4.52


General Counsel and Chief Compliance Officer
12/11/2019 M 24090 A
12/11/2019 F 8271 D $4.52

Senior Vice President, Corporate Strategy and Chief Financial Officer
12/11/2019 M 80300 A
12/11/2019 F 27766 D $4.52

Chief Executive Officer
12/11/2019 M 238800 A
12/11/2019 F 85210 D $4.52
12/11/2019 M 14000 A $1.83